We show that NL-CVX1, a de novo human angiotensin-converting enzyme 2 protein decoy that blocks viral cell invasion, prevents severe disease after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in mice and may constitute a potent anti–SARS-CoV-2 treatment. Here, ACE2 is linked to COVID-19.